KNIGHT THERAPEUTICS INC (GUD.CA) Stock Price, Forecast & Analysis
Canada - TSX:GUD - CA4990531069 - Common Stock
GUD.CA Key Statistics, Chart & Performance
The current stock price of GUD.CA is 6.05 CAD. In the past month the price increased by 2.72%. In the past year, price increased by 15.02%.
GUD.CA Latest News, Press Relases and Analysis
GUD.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.73 | 3.45B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.95B | ||
| CRON.CA | CRONOS GROUP INC | 24.79 | 1.33B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.13 | 846.06M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 558.11M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 20.74 | 341.31M | ||
| HITI.CA | HIGH TIDE INC | N/A | 362.00M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 358.88M | ||
| TSND.CA | TERRASCEND CORP | N/A | 351.25M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 290.15M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 254.00M | ||
| XLY.CA | AUXLY CANNABIS GROUP INC | 5.17 | 208.98M |
Related stock screener links
About GUD.CA
Company Profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
Company Info
KNIGHT THERAPEUTICS INC
3400 De Maisonneuve Blvd W
MONTREAL QUEBEC H3Z 3B8 CA
CEO: Jonathan Ross Goodman
Employees: 745
Phone: 15144844483
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you describe the business of KNIGHT THERAPEUTICS INC?
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
Can you provide the latest stock price for KNIGHT THERAPEUTICS INC?
The current stock price of GUD.CA is 6.05 CAD. The price decreased by -0.33% in the last trading session.
Does GUD stock pay dividends?
GUD.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of GUD stock?
GUD.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about KNIGHT THERAPEUTICS INC (GUD.CA) stock?
11 analysts have analysed GUD.CA and the average price target is 7.96 CAD. This implies a price increase of 31.5% is expected in the next year compared to the current price of 6.05.
What is the employee count for GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) currently has 745 employees.
GUD.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GUD.CA. When comparing the yearly performance of all stocks, GUD.CA turns out to be only a medium performer in the overall market: it outperformed 41.91% of all stocks.
GUD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA. GUD.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GUD.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.1% | ||
| ROA | 0.04% | ||
| ROE | 0.05% | ||
| Debt/Equity | 0.11 |
GUD.CA Forecast & Estimates
11 analysts have analysed GUD.CA and the average price target is 7.96 CAD. This implies a price increase of 31.5% is expected in the next year compared to the current price of 6.05.
For the next year, analysts expect an EPS growth of -330.28% and a revenue growth 14.81% for GUD.CA